Fatty-Acid Binding Protein 4 (FABP4) as a Potential Preclinical Biomarker of Drug-Induced Kidney Injury
- 24 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 166 (2) , 441-450
Abstract
Identification of improved translatable biomarkers of nephrotoxicity is an unmet safety biomarker need. Fatty-acid-binding protein 4 (FABP4) was previously found to be associated with clinical renal dysfunction and was proposed as a biomarker of glomerular damage. The aim of this study was to evaluate FABP4 as a potential preclinical biomarker of drug-induced kidney injury (DIKI). Han-Wistar rats were dosed with cisplatin [2.5 mg/kg, single, intraperitoneally (i.p.)], puromycin (10 mg/kg, daily, i.p.) or N-phenylanthranylic acid [NPAA, 500 mg/kg, daily, per os (p.o.)] over a 28-day period to induce proximal tubule, glomerular or collecting duct injury, respectively. An increase in urinary FABP4 levels was observed on days 1 and 3 after NPAA treatment and on days 14, 21, and 28 after puromycin treatment, whereas cisplatin treatment had no effect. No significant changes were reported for plasma levels of FABP4 after any treatment. Interestingly, immunohistochemical analysis showed a marked decrease in FABP4 expression in the loop of Henle on day 7 after NPAA treatment and a complete loss of FABP4 expression on day 14 after puromycin treatment. The magnitude of increase in FABP4 urinary levels in response to NPAA and puromycin was higher than for established preclinical biomarkers serum creatinine, clusterin, or cystatin C. Our results suggest that FABP4 has the potential for preclinical application as a biomarker of DIKI.Keywords
Funding Information
- Walloon Region (N°7245)
This publication has 31 references indexed in Scilit:
- Role of New Biomarkers: Functional and Structural DamageCritical Care Research and Practice, 2013
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- Next-generation biomarkers for detecting kidney toxicityNature Biotechnology, 2010
- An Attempt to Understand Kidney's Protein Handling Function by Comparing Plasma and Urine ProteomesPLOS ONE, 2009
- Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injuryAmerican Journal of Physiology-Renal Physiology, 2009
- Biomarkers for the Diagnosis of Acute Kidney InjuryNephron Clinical Practice, 2008
- Renal L-Type Fatty Acid–Binding Protein in Acute Ischemic InjuryJournal of the American Society of Nephrology, 2007
- Urinary Excretion of Liver-Type Fatty Acid–Binding Protein in Contrast Medium–Induced NephropathyAmerican Journal of Kidney Diseases, 2006
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- 1H-Nuclear magnetic resonance pattern recognition studies withN-phenylanthranilic acid in the rat: time- and dose-related metabolic effectsBiomarkers, 2003